A new study is showing a policy change in 2016 related to the vaccination of some premature babies for RSV in Nova Scotia led to a tenfold increase in the number of infants in that group that were ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

14 days Prescribing information Palivizumab powder and solution Synagis (MedImmune) Lifetime cumulative exposure for 14 days Manufacturer Pancuronium bromide injection Pavulon (Gensia/Sicor ...

Obviously, we have Capvaxive, which is launching as we speak. We have palivizumab, a monoclonal antibody for RSV, that we hope to get approval and see come before the RSV season this year.

Sobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain conditional payments. As part of the deal, first announced in August ...

It will compete with Sobi's Synagis (palivizumab), an antibody originated by AZ, which is dosed once a month. Today, AZ and Sanofi revealed the results of a second phase 3 trial – MELODY ...

This came after AstraZeneca presented the proposal to conduct a Phase IV clinical trial titled “A Multicentre, Interventional, Phase IV, Open-label Study to Evaluate the Safety of Palivizumab in ...

Two are monoclonal antibodies (nirsevimab and palivizumab), and the third is a vaccine provided during pregnancy (RSVpreF) from 32 to 36 weeks gestation. Massaro says her son, Angus, contracted RSV ...